Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1-(4-Isopropoxyphenyl)ethanone is an organic compound with the chemical structure featuring an ethanone group connected to a phenyl ring with an isopropoxy substituent at the para position. It is a versatile intermediate in the synthesis of various chemical compounds and has potential applications in different industries.

4074-51-5

Post Buying Request

4074-51-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4074-51-5 Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Isopropoxyphenyl)ethanone is used as a synthetic intermediate for the preparation of p-substituted acetophenone compounds, which are essential in the development of pharmaceuticals with diverse therapeutic applications, including the treatment of various diseases and disorders.
Used in Chemical Synthesis:
1-(4-Isopropoxyphenyl)ethanone serves as a key building block in the synthesis of a wide range of organic compounds, such as dyes, pigments, and other specialty chemicals. Its unique structure allows for further functionalization and modification, making it a valuable component in the development of new materials and products.
Used in Research and Development:
Due to its structural characteristics, 1-(4-isopropoxyphenyl)ethanone is also utilized in research and development for the exploration of new chemical reactions, mechanisms, and the synthesis of novel compounds with potential applications in various fields, such as materials science, pharmaceuticals, and agrochemicals.

Check Digit Verification of cas no

The CAS Registry Mumber 4074-51-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,0,7 and 4 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 4074-51:
(6*4)+(5*0)+(4*7)+(3*4)+(2*5)+(1*1)=75
75 % 10 = 5
So 4074-51-5 is a valid CAS Registry Number.
InChI:InChI=1/C11H14O2/c1-8(2)13-11-6-4-10(5-7-11)9(3)12/h4-8H,1-3H3

4074-51-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(4-propan-2-yloxyphenyl)ethanone

1.2 Other means of identification

Product number -
Other names 1-acetyl-4-(methylethoxy)benzene

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:4074-51-5 SDS

4074-51-5Relevant articles and documents

NEGATIVE ALLOSTERIC MODULATION OF GLUN3-CONTAINING N-METHYL-D-ASPARTATE RECEPTORS

-

Page/Page column 73, (2021/08/06)

Disclosed are negative allosteric modulators of GluN3-containing NMDA receptors. In general, these compounds are highly selective for GluN3 (such as GluN3A and/or GluN3B) over GluN1 and/or GluN2. They can function as non-competitive antagonists with activity that is independent of membrane potential, glycine concentration, and extracellular pH. Also disclosed are pharmaceutical formulations of the negative allosteric modulators. These compounds can be used to enhance synaptic function and/or treating a neurological condition or disorder. Exemplary neurological conditions or disorders include, but are not limited to, major mental disorders, conditions that involve basal ganglia or altered dopamine, substance abuse/addiction or predisposition to substance abuse/addiction, pain disorders, developmental delay or situations with impaired learning, memory, and/or cognition, acute neuronal or glial injuries, and circuit disorders.

Solar-driven tandem photoredox nickel-catalysed cross-coupling using modified carbon nitride

Qin, Yangzhong,Martindale, Benjamin C. M.,Sun, Rui,Rieth, Adam J.,Nocera, Daniel G.

, p. 7456 - 7461 (2020/08/03)

Nickel-catalysed aryl amination and etherification are driven with sunlight using a surface-modified carbon nitride to extend the absorption of the photocatalyst into a wide range of the visible region. In contrast to traditional homogeneous photochemical methodologies, the lower cost and higher recyclability of the metal-free photocatalyst, along with the use of readily available sunlight, provides an efficient and sustainable approach to promote nickel-catalysed cross-couplings. This journal is

Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2

Conlon, Ivie L.,Drennen, Brandon,Lanning, Maryanna E.,Hughes, Samuel,Rothhaas, Rebecca,Wilder, Paul T.,MacKerell, Alexander D.,Fletcher, Steven

, p. 1691 - 1698 (2020/07/04)

Protein–protein interactions (PPIs), many of which are dominated by α-helical recognition domains, play key roles in many essential cellular processes, and the dysregulation of these interactions can cause detrimental effects. For instance, aberrant PPIs involving the Bcl-2 protein family can lead to several diseases including cancer, neurodegenerative diseases, and diabetes. Interactions between Bcl-2 pro-life proteins, such as Mcl-1, and pro-death proteins, such as Bim, regulate the intrinsic pathway of apoptosis. p53, a tumor-suppressor protein, also has a pivotal role in apoptosis and is negatively regulated by its E3 ubiquitin ligase HDM2. Both Mcl-1 and HDM2 are upregulated in numerous cancers, and, interestingly, there is crosstalk between both protein pathways. Recently, synergy has been observed between Mcl-1 and HDM2 inhibitors. Towards the development of new anticancer drugs, we herein describe a polypharmacology approach for the dual inhibition of Mcl-1 and HDM2 by employing three densely functionalized isoxazoles, pyrazoles, and thiazoles as mimetics of key α-helical domains of their partner proteins.

Identification of new aryl hydrocarbon receptor (AhR) antagonists using a zebrafish model

Jeong, Jieun,Kim, Kun-Hee,Kim, Dong-Young,Chandrasekaran, Gopalakrishnan,Kim, Minhee,Pagire, Suvarna H.,Dighe, Mahesh,Choi, Eun Young,Bak, Su-Min,Kim, Eun-Young,Shin, Myung-Geun,Choi, Seok-Yong,Ahn, Jin Hee

, (2019/08/01)

A new series of 1,3-diketone, heterocyclic and α,β-unsaturated derivatives were synthesized and evaluated for their AhR antagonist activity using zebrafish and mammalian cells. Compounds 1b, 2c, 3b and 5b showed significant AhR antagonist activity in a transgenic zebrafish model. Among them, compound 3b, and 5b were found to have excellent AhR antagonist activity with IC50 of 3.36 nM and 8.3 nM in a luciferase reporter gene assay. In stem cell proliferation assay, compound 5b elicited marked HSC expansion.

Chalcone derivatives enhance ATP-binding cassette transporters A1 in human THP-1 macrophages

Teng, I-Jou,Tsai, Min-Chien,Shih, Shao-Fu,Tsuei, Bi-Feng,Chang, Hsin,Chuang, Yi-Ping,Lin, Chin-Sheng,Chern, Ching-Yuh,Chen, Sy-Jou

, (2018/07/13)

Atherosclerosis is a process of imbalanced lipid metabolism in the vascular walls. The underlying pathology mainly involves the deposition of oxidized lipids in the endothelium and the accumulation of cholesterol in macrophages. Macrophages export excessive cholesterol (cholesterol efflux) through ATP-binding cassette transporter A1 (ABCA1) to counter the progression of atherosclerosis. We synthesized novel chalcone derivatives and assessed their effects and the underlying mechanisms on ABCA1 expression in macrophages. Human THP-1 macrophages were treated with synthetic chalcone derivatives for 24 h. In Western blot and flow cytometry analyses, a chalcone derivative, (E)-1-(3,4-diisopropoxyphenyl)-3-(4-isopropoxy-3-methoxyphenyl)prop- 2-en-1-one (1m), was observed to significantly enhance ABCA1 protein expression in THP-1 cells (10 μM, 24 h). Levels of mRNA of ABCA1 and liver X receptor alpha (LXRα) were quantified using a real-time quantitative polymerase chain reaction technique and were found to be significantly increased after treatment with the novel chalcone derivative 1m. Several microRNAs, including miR155, miR758, miR10b, miR145, miR33, and miR106b, which functionally inhibit ABCA1 expression were suppressed after treatment with 1m. Collectively, 1m increases ABCA1 expression in human THP-1 macrophages. The mechanisms involve the activation of the LXRα-ABCA1 pathway and suppression of certain microRNAs that regulate ABCA1 expression.

Palladium-Catalyzed 2,2,2-Trifluoroethoxylation of Aromatic and Heteroaromatic Chlorides Utilizing Borate Salt and the Synthesis of a Trifluoro Analogue of Sildenafil

Peth?, Bálint,Zwillinger, Márton,Csenki, János T.,Káncz, Anna E.,Krámos, Balázs,Müller, Judit,Balogh, Gy?rgy T.,Novák, Zoltán

supporting information, p. 15628 - 15632 (2017/10/20)

A simple and convenient method was developed for the introduction of a 2,2,2-trifluoroethoxy group to various aromatic and heteroaromatic systems. The novel process utilizes aromatic chlorides as substrates, and tetrakis(2,2,2-trifluoroethoxy) borate salt as an inexpensive and readily available fluoroalkoxy source in a palladium-catalyzed cross-coupling reaction. The power of the developed methodology was demonstrated in the synthesis of a fluorous derivative of Sildenafil.

Phenanthrene Compound, Ramification Thereof And Drug Composition Containing Phenanthrene Compound Or Ramification And Used For Treating Tuberculosis

-

Paragraph 0165; 0166; 0168, (2016/11/24)

The present invention relates to a novel phenanthrene compound, a ramification thereof and a drug composition containing the phenanthrene compound or the ramification and used for preventing or treating tuberculosis. The above tuberculosis activity resistant compound has excellent activity for the drug-fast MDR-MTB, also has a characteristic of low cytotoxicity, and can be used as the drug composition used for preventing or treating tuberculosis.

CARBONYL ERASTIN ANALOGS AND THEIR USE

-

Paragraph 0316; 0317; 0318, (2016/12/01)

The present invention provides, inter alia, compounds having the structure of formula (I): Compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer havi

Pro-angiogenic effects of chalcone derivatives in zebrafish embryos in vivo

Chen, Yau-Hung,Chang, Chao-Yuan,Chang, Chiung-Fang,Chen, Po-Chih,Lee, Ya-Ting,Chern, Ching-Yuh,Tsai, Jen-Ning

, p. 12512 - 12524 (2015/08/06)

The aim of this study was to investigate novel chalcones with potent angiogenic activities in vivo. Chalcone-based derivatives were evaluated using a transgenic zebrafish line with fluorescent vessels to real-time monitor the effect on angiogenesis. Results showed that the chalcone analogues did not possess anti-angiogenic effect on zebrafish vasculatures; instead, some of them displayed potent pro-angiogenic effects on the formation of the sub-intestinal vein. Similar pro-angiogenic effects can also be seen on wild type zebrafish embryos. Moreover, the expression of vegfa, the major regulator for angiogenesis, was also upregulated in their treatment. Taken together, we have synthesized and identified a series of novel chalcone-based derivatives as potent in vivo pro-angiogenic compounds. These novel compounds hold potential for therapeutic angiogenesis.

Switching on elusive organometallic mechanisms with photoredox catalysis

Terrett, Jack A.,Cuthbertson, James D.,Shurtleff, Valerie W.,MacMillan, David W.C.

, p. 330 - 334 (2015/09/01)

Transition-metal-catalysed cross-coupling reactions have become one of the most used carbon-carbon and carbon-heteroatom bond-forming reactions in chemical synthesis. Recently, nickel catalysis has been shown to participate in a wide variety of C-C bond-forming reactions, most notably Negishi, Suzuki-Miyaura, Stille, Kumada and Hiyama couplings. Despite the tremendous advances in C-C fragment couplings, the ability to forge C-O bonds in a general fashion via nickel catalysis has been largely unsuccessful. The challenge for nickel-mediated alcohol couplings has been the mechanistic requirement for the critical C-O bond-forming step (formally known as the reductive elimination step) to occur via a Ni(iii) alkoxide intermediate. Here we demonstrate that visible-light-excited photoredox catalysts can modulate the preferred oxidation states of nickel alkoxides in an operative catalytic cycle, thereby providing transient access to Ni(iii) species that readily participate in reductive elimination. Using this synergistic merger of photoredox and nickel catalysis, we have developed a highly efficient and general carbon-oxygen coupling reaction using abundant alcohols and aryl bromides. More notably, we have developed a general strategy to 'switch on' important yet elusive organometallic mechanisms via oxidation state modulations using only weak light and single-electron-transfer catalysts.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 4074-51-5